Opinion of the Transparency Council – bevacizumab
At its meeting on 27 January 2025, the Transparency Council adopted opinion No. 15/2025 on covering the reimbursement of medicines containing the active substance bevacizumab within the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. treatment of CRVO and BRVO (central retinal vein and branch vein thrombosis) within the framework of drug program B.70 “Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0)”